Plasma cholesteryl ester transfer protein and lipoprotein levels during treatment of growth hormone-deficient adult humans.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

In this study the effect of human recombinant growth hormone (hrGH) replacement therapy administered to GH-deficient adults on the plasma cholesteryl ester transfer protein (CETP) concentration and activity was analyzed.

These findings were related to changes in the concentrations of the plasma lipoproteins.

Who Took Part

The study group was 8 men.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a double-blind study.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

During the study plasma lipoproteins were separated by ultracentrifugation, and plasma cholesterol esterification rate (CER), endogenous CETP activity, and CETP concentration were measured.

What Was Measured

The subject headings attached to it are Carrier Proteins, Cholesterol Ester Transfer Proteins, Cholesterol, HDL, Dwarfism, Pituitary, Glycoproteins, Human Growth Hormone and Lipoprotein(a).

What This Means in Plain Language

The paper is a double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 8 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2001 (Lipids), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.